Cortical hyperostosis: a complication of prostaglandin E1 treatment in congenital heart disease.

M H, Smet; G, Marchal; L, Lambert; H, Devlieger; M, Gewillig

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 1990

Data sources: Europe PubMed Central

Cortical hyperostosis: a complication of prostaglandin E1 treatment in congenital heart disease.

descriptionPublicationkeyboard_double_arrow_right Article 02 Feb 1990 English Journal:Journal belge de radiologie, volume 72 (issn: 0302-7430,

Copyright policy )

Authors: M H, Smet; G, Marchal; L, Lambert; H, Devlieger; M, Gewillig;

pmid: 2600053

Cortical hyperostosis: a complication of prostaglandin E1 treatment in congenital heart disease.

- Summary
- Subjects
- Metrics

Abstract

Prostaglandin E1 (PGE1) is an essential drug for infants with ductal-dependent congenital heart disease. Cortical hyperostosis of the long bones is one of the complications during and after PGE1 therapy and should be considered in the differential diagnosis of periostitis in the infant.

Keywords

Heart Defects, Congenital, Male, Radiography, Pulmonary Valve, Periosteum, Infant, Newborn, Humans, Alprostadil, Hyperostosis

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average